Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review

被引:78
|
作者
Ye, Zhi-Kang [1 ,2 ]
Li, Can [1 ,2 ]
Zhai, Suo-Di [1 ]
机构
[1] Peking Univ, Hosp 3, Dept Pharm, Beijing 100871, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing 100871, Peoples R China
来源
PLOS ONE | 2014年 / 9卷 / 06期
关键词
SERUM CONCENTRATIONS; INFECTIONS; CONSENSUS; QUALITY; NEED;
D O I
10.1371/journal.pone.0099044
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and Objective: Despite the availability of clinical practice guidelines (CPGs) for therapeutic drug monitoring (TDM) of vancomycin, vancomycin serum concentrations still do not reach therapeutic concentrations in many patients. Thus, we sought to systematically review the quality and consistency of recommendations for an international cohort of CPGs regarding vancomycin TDM. Methods: PubMed, Embase, guidelines' websites and Google were searched for CPGs for vancomycin TDM. Two independent assessors rated the quality of each CPG using the Appraisal of Guidelines for Research & Evaluation II (AGREEII) instrument and data were independently extracted. Results: Twelve guidelines were evaluated and the overall quality of guidelines for vancomycin TDM was moderate. The highest score was recorded in the domain of clarity of presentation, and the lowest score was recorded in the domain of rigor of development and stakeholder involvement. The specific recommendations for vancomycin TDM were moderately consistent and guidelines varied in trough concentration monitoring, frequency of TDM, and serum concentration targets. Conclusion: The overall guideline quality for vancomycin TDM was not optimal and effort is needed to improve guideline quality, especially in the domain of rigor of development and stakeholder involvement.
引用
下载
收藏
页数:8
相关论文
共 50 条
  • [31] Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
    Okada, Kenji
    Kimura, Toshimi
    Mikamo, Hiroshige
    Kasahara, Kei
    Seki, Masafumi
    Takakura, Shunji
    Tokimatsu, Issei
    Ohmagari, Norio
    Takahashi, Yoshiko
    Matsumoto, Kazuaki
    Igarashi, Masahiro
    Kobayashi, Masahiro
    Hamada, Yukihiro
    Mochizuki, Takahiro
    Kimura, Masao
    Nishi, Yoshifumi
    Tanigawara, Yusuke
    Takesue, Yoshio
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (1-2) : 1 - 5
  • [32] The guideline for therapeutic drug monitoring guidelines development
    Zeng, Linan
    Yi, Qiusha
    Huang, Liang
    Chen, Wenqian
    Men, Peng
    Zhang, Jingjing
    Jiang, Zhimei
    Miao, Liyan
    Zhao, Rongsheng
    Zhang, Xianglin
    Zhang, Lingli
    JOURNAL OF EVIDENCE BASED MEDICINE, 2022, 15 (03) : 272 - 283
  • [33] Consensus guidelines for therapeutic drug monitoring in psychiatry
    Laux, G
    PSYCHOPHARMAKOTHERAPIE, 2005, 12 (05): : 165 - 165
  • [34] Utility of therapeutic drug monitoring in chronic myeloid leukemia: A systematic review
    Garcia Ferrer, Manuel
    Wojnicz, Aneta
    Abad Santos, Francisco
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 18 - 19
  • [35] A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants
    Hutchinson, Laura
    Sinclair, Marlene
    Reid, Bernadette
    Burnett, Kathryn
    Callan, Bridgeen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (06) : 1089 - 1108
  • [36] Clinical utility of therapeutic drug monitoring of antiepileptic drugs Systematic review
    Al-Roubaie, Zanab
    Guadagno, Elena
    Ramanakumar, Agnihotram V.
    Khan, Afsheen Q.
    Myers, Kenneth A.
    NEUROLOGY-CLINICAL PRACTICE, 2020, 10 (04) : 344 - 355
  • [37] The impact of daptomycin therapeutic drug monitoring on clinical outcomes: a systematic review
    Cairns, Kelly A.
    Abbott, Iain J.
    Dooley, Michael J.
    Peleg, Anton Y.
    Peel, Trisha N.
    Udy, Andrew A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (02)
  • [38] THERAPEUTIC MONITORING OF VANCOMYCIN IN CHILDREN: IS THERE A COST TO NON-ADHERENCE OF GUIDELINES?
    Firth, S. D.
    Yakub, S. Y.
    Sherwin, C. M.
    Korgenski, K.
    Constance, J. E.
    Stockmann, C.
    Balch, A.
    Spigarelli, M. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S56 - S56
  • [39] Therapeutic drug monitoring - A review
    Ashavaid T.F.
    Dheraj A.J.
    Indian Journal of Clinical Biochemistry, 1999, 14 (1) : 91 - 94
  • [40] Therapeutic Monitoring of Vancomycin in Neonates: Is There a Cost to Non-adherence of Guidelines?
    Firth, S. D.
    Yakub, S. Y.
    Sherwin, C. M. T.
    Korgenski, E. K.
    Constance, J. E.
    Balch, A.
    Spigarelli, M. G.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 681 - 681